PT  - JOURNAL ARTICLE
AU  - HUILI ZHENG
AU  - YAN WANG
AU  - CHUANNING TANG
AU  - LINDSEY JONES
AU  - HUA YE
AU  - GUANGCHUN ZHANG
AU  - WEIHAI CAO
AU  - JINGWEN LI
AU  - LIFENG LIU
AU  - ZHENCONG LIU
AU  - CHAO ZHANG
AU  - FENG LOU
AU  - ZHIYUAN LIU
AU  - YANGYANG LI
AU  - ZHENFEN SHI
AU  - JINGBO ZHANG
AU  - DANDAN ZHANG
AU  - HONG SUN
AU  - HAICHAO DONG
AU  - ZHISHOU DONG
AU  - BAISHUAI GUO
AU  - HE YAN
AU  - QINGYU LU
AU  - XUE HUANG
AU  - SI-YI CHEN
TI  - <em>TP53, PIK3CA, FBXW7</em> and <em>KRAS</em> Mutations in Esophageal Cancer Identified by Targeted Sequencing
DP  - 2016 May 01
TA  - Cancer Genomics - Proteomics
PG  - 231--238
VI  - 13
IP  - 3
4099  - http://cgp.iiarjournals.org/content/13/3/231.short
4100  - http://cgp.iiarjournals.org/content/13/3/231.full
SO  - Cancer Genomics Proteomics2016 May 01; 13
AB  - Background/Aim: Esophageal cancer (EC) is a common malignancy with significant morbidity and mortality. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in EC that may serve as biomarkers might help predict patient outcome and guide treatment. Traditionally, personalized cancer DNA sequencing was impractical and expensive. Recent technological advancements have made targeted DNA sequencing more cost- and time-effective with reliable results. This technology may be useful for clinicians to direct patient treatment. Materials and Methods: The Ion PGM and AmpliSeq Cancer Panel was used to identify mutations at 737 hotspot loci of 45 cancer-related genes in 64 EC samples from Chinese patients. Results: Frequent mutations were found in TP53 and less frequent mutations in PIK3CA, FBXW7 and KRAS. Conclusion: These results demonstrate that targeted sequencing can reliably identify mutations in individual tumors that make this technology a possibility for clinical use.